ReviewCancer2015
Ovarian cancer treatment: The end of empiricism?
Review in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- RAD51 protein is a predictor of chemosensitivity and survival prognosis in patients with advanced high-grade serous ovarian cancer undergoing neoadjuvant chemotherapy.Frontiers in oncology · 2025Article
- CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.Journal of nanobiotechnology · 2024Article
- RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma.Journal of gynecologic oncology · 2023Article
- Article
- Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.Journal for immunotherapy of cancer · 2022Article
- Identification of a novel pyridine derivative with inhibitory activity against ovarian cancer progressionFrontiers in pharmacology · 2022Article
- Effect of Cerenkov Radiation-Induced Photodynamic Therapy withInternational journal of molecular sciences · 2021Article
- SurgeryGland surgery · 2020Review
- Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Article
- Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.Cancer immunology research · 2019Article
- Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).International journal of clinical oncology · 2019Observational
- Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.Genome medicine · 2018Article
- Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.Oncology letters · 2017Article
- NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo.Journal of hematology & oncology · 2016Article
- Efficacy of Postoperative Hormone Replacement Therapy on Prognosis of Patients with Serous Ovarian Carcinoma.Chinese medical journal · 2016Article
- Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.Journal of ovarian research · 2016Article
- Article
- Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.American journal of cancer research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis, investigation, and management of ovarian cancer are in a state of flux-balancing ever rapid advances in our understanding of its biology with 3 decades of clinical trials. Clinical trials that started with empirically driven selections have evolved in an evidence-informed manner to gradually improve outcome. Has this improved understanding of the biology and associated calls to action led to appropriate changes in therapy? In this review, the authors discuss incorporating emerging data on biology, combinations, dose, and scheduling of new and existing agents with patient preferences in the management of women with ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.